|
1
|
Pitti RM, Marsters SA, Ruppert S, Donahue
CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2
ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falschlehner C, Emmerich CH, Gerlach B and
Walczak H: TRAIL signalling: Decisions between life and death. Int
J Biochem Cell Biol. 39:1462–1475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Dijk M, Halpin-McCormick A, Sessler T,
Samali A and Szegezdi E: Resistance to TRAIL in non-transformed
cells is due to multiple redundant pathways. Cell Death Dis.
4:e7022013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rippo MR, Moretti S, Vescovi S, Tomasetti
M, Orecchia S, Amici G, Catalano A and Procopio A: FLIP
overexpression inhibits death receptor-induced apoptosis in
malignant mesothelial cells. Oncogene. 23:7753–7760. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Yue P, Khuri FR and Sun SY: Decoy
receptor 2 (DcR2) is a p53 target gene and regulates
chemosensitivity. Cancer Res. 65:9169–9175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hetschko H, Voss V, Horn S, Seifert V,
Prehn JH and Kögel D: Pharmacological inhibition of Bcl-2 family
members reactivates TRAIL-induced apoptosis in malignant glioma. J
Neurooncol. 86:265–272. 2008. View Article : Google Scholar
|
|
10
|
Zhou J, Lu GD, Ong CS, Ong CN and Shen HM:
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis
via p53-mediated death receptor 4 up-regulation. Mol Cancer Ther.
7:2170–2180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ganten TM, Haas TL, Sykora J, Stahl H,
Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel
W, et al: Enhanced caspase-8 recruitment to and activation at the
DISC is critical for sensitisation of human hepatocellular
carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic
drugs. Cell Death Differ. 11(Suppl 1): S86–S96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pathil A, Armeanu S, Venturelli S,
Mascagni P, Weiss TS, Gregor M, Lauer UM and Bitzer M: HDAC
inhibitor treatment of hepatoma cells induces both
TRAIL-independent apoptosis and restoration of sensitivity to
TRAIL. Hepatology. 43:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song JH, Tse MC, Bellail A, Phuphanich S,
Khuri F, Kneteman NM and Hao C: Lipid rafts and nonrafts mediate
tumor necrosis factor related apoptosis-inducing ligand induced
apoptotic and nonapoptotic signals in non small cell lung carcinoma
cells. Cancer Res. 67:6946–6955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu J, Zhou JY, Wei WZ and Wu GS:
Activation of the Akt survival pathway contributes to TRAIL
resistance in cancer cells. PLoS One. 5:e102262010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Dittmer MR, Blackwell K, Workman
LM, Hostager B and Habelhah H: TRAIL activates JNK and NF-κB
through RIP1-dependent and -independent pathways. Cell Signal.
27:306–314. 2015. View Article : Google Scholar
|
|
16
|
Secchiero P, Gonelli A, Carnevale E,
Milani D, Pandolfi A, Zella D and Zauli G: TRAIL promotes the
survival and proliferation of primary human vascular endothelial
cells by activating the Akt and ERK pathways. Circulation.
107:2250–2256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang XD, Borrow JM, Zhang XY, Nguyen T
and Hersey P: Activation of ERK1/2 protects melanoma cells from
TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from
mitochondria. Oncogene. 22:2869–2881. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y and Zhang B: TRAIL resistance of
breast cancer cells is associated with constitutive endocytosis of
death receptors 4 and 5. Mol Cancer Res. 6:1861–1871. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han J, Goldstein LA, Gastman BR and
Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of
TRAIL-mediated mitochondrial apoptosis. J Biol Chem.
281:10153–10163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
MacFarlane M, Inoue S, Kohlhaas SL, Majid
A, Harper N, Kennedy DB, Dyer MJ and Cohen GM: Chronic lymphocytic
leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death
Differ. 12:773–782. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lemke J, Noack A, Adam D, Tchikov V,
Bertsch U, Röder C, Schütze S, Wajant H, Kalthoff H and Trauzold A:
TRAIL signaling is mediated by DR4 in pancreatic tumor cells
despite the expression of functional DR5. J Mol Med (Berl).
88:729–740. 2010. View Article : Google Scholar
|
|
22
|
Kelley RF, Totpal K, Lindstrom SH, Mathieu
M, Billeci K, Deforge L, Pai R, Hymowitz SG and Ashkenazi A:
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor
necrosis factor-related apoptosis-inducing ligand reveal a greater
contribution of death receptor (DR) 5 than DR4 to apoptosis
signaling. J Biol Chem. 280:2205–2212. 2005. View Article : Google Scholar
|
|
23
|
Lim SC, Duong HQ, Choi JE, Lee TB, Kang
JH, Oh SH and Han SI: Lipid raft-dependent death receptor 5 (DR5)
expression and activation are critical for ursodeoxycholic
acid-induced apoptosis in gastric cancer cells. Carcinogenesis.
32:723–731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung EM, Park JW, Choi KS, Park JW, Lee
HI, Lee KS and Kwon TK: Curcumin sensitizes tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis
through CHOP-independent DR5 upregulation. Carcinogenesis.
27:2008–2017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gómez-Benito M, Martinez-Lorenzo MJ, Anel
A, Marzo I and Naval J: Membrane expression of DR4, DR5 and
caspase-8 levels, but not Mcl-1, determine sensitivity of human
myeloma cells to Apo2L/TRAIL. Exp Cell Res. 313:2378–2388. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gonzalvez F and Ashkenazi A: New insights
into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Linderoth E, Pilia G, Mahajan NP and Ferby
I: Activated Cdc42-associated kinase 1 (Ack1) is required for tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor
recruitment to lipid rafts and induction of cell death. J Biol
Chem. 288:32922–32931. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Azijli K, Weyhenmeyer B, Peters GJ, de
Jong S and Kruyt FA: Non-canonical kinase signaling by the death
ligand TRAIL in cancer cells: Discord in the death receptor family.
Cell Death Differ. 20:858–868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen S, Fu L, Raja SM, Yue P, Khuri FR and
Sun SY: Dissecting the roles of DR4, DR5 and c-FLIP in the
regulation of geranylgeranyltransferase I inhibition-mediated
augmentation of TRAIL-induced apoptosis. Mol Cancer. 9:232010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han J, Hou W, Goldstein LA, Lu C, Stolz
DB, Yin XM and Rabinowich H: Involvement of protective autophagy in
TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem.
283:19665–19677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mahalingam D, Keane M, Pirianov G, Mehmet
H, Samali A and Szegezdi E: Differential activation of JNK1
isoforms by TRAIL receptors modulate apoptosis of colon cancer cell
lines. Br J Cancer. 100:1415–1424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ganten TM, Koschny R, Haas TL, Sykora J,
Li-Weber M, Herzer K and Walczak H: Proteasome inhibition
sensitizes hepatocellular carcinoma cells, but not human
hepatocytes, to TRAIL. Hepatology. 42:588–597. 2005. View Article : Google Scholar : PubMed/NCBI
|
